Exchangeable APOA1 on HDL inhibits LDL binding to proteoglycans.

Area of Science:

• Biochemistry
• Cardiovascular Biology
• Molecular Medicine

Background:

• Atherosclerosis development involves low-density lipoprotein (LDL) entrapment by arterial wall proteoglycans (PGs).
• High-density lipoproteins (HDL) are known to modulate this process, but the precise mechanisms remain unclear.

Purpose of the Study:

• To elucidate how HDL inhibits the binding of LDL to PGs in the arterial extracellular matrix (ECM).

Main Methods:

• In-cell ELISA to quantify LDL-PG binding in mouse vascular smooth muscle cells.
• Biochemical techniques including Fast Protein Liquid Chromatography, immunoprecipitation, SDS-PAGE, and immunoblotting were used to analyze HDL and apolipoprotein interactions.

Main Results:

• HDL and apolipoprotein A1 (APOA1) demonstrated dose-dependent inhibition of LDL-PG binding.
• APOA1 dissociated from HDL and bound to LDL, impairing LDL's ability to attach to PGs.
• HDL's inhibitory effect was abolished when APOA1 was rigidly bound to HDL particles.

Conclusions:

• HDL inhibits LDL-PG binding via loosely attached, lipid-free APOA1 on its surface.
• Lipid-free APOA1 is identified as a key mediator in reducing arterial LDL retention.
• These findings offer novel insights into HDL's protective role against atherosclerosis.